country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-185390

Copy Link Print Information

Verteporfin liposome

(Synonyms: Liposomal verteporfin)

Liposomal verteporfin is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy, which generates reactive oxygen species (ROS) upon irradiation at 690 nm to mediate photodynamic effects. Liposomal verteporfin can promote the release of Oxaliplatin (HY-17371) from endolysosomes via photochemical internalization (PCI), prolong the drug circulation time and enable sustained release, accumulate the drug in neovascular vessels, and enhance its cytotoxicity in tumor models. Liposomal verteporfin can be used in studies related to neovascular eye diseases and pancreatic cancer^[1][2]^[3].

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Verteporfin liposome Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle YAP Isoform-spezifische Produkte anzeigen :

In Vitro

Verteporfin liposome (0.01-0.8 μM; 1 h) exhibits extremely low dark toxicity in MIA PaCa-2 and PANC-1 pancreatic cancer cells, and induces concentration-dependent cytotoxicity after irradiation with 0.5 J/cm²^[1].
Verteporfin liposome (25-250 μM; 0.5-24 h) is taken up by MIA PaCa-2 and PANC-1 3D microtumors in a time-dependent manner^[1].
Photodynamic therapy (PDT) with Verteporfin liposome (100 μM; 8 h) synergizes with Oxaliplatin (HY-17371) to reduce the viability of 3D pancreatic cancer microtumors of MIA PaCa-2 and PANC-1^[1].
Verteporfin liposomes are taken up faster by LDL receptor-enriched human colon cancer cell lines than aqueous sodium hematoporphyrin^[3].
Strong lysosomal colocalization is observed in MIA PaCa-2 and PANC-1 pancreatic cancer cells treated with Verteporfin liposome (200 μM; 2, 8, 24 h)^[1].
The binding rate of Verteporfin liposome to plasma lipoproteins in vitro reaches up to 91%, with a balanced distribution among major lipoprotein fractions^[3].
Verteporfin liposomes are selectively taken up by LDL receptor-positive cell lines in vitro via LDL receptor-mediated binding^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

MIA PaCa-2, PANC-1
Concentration:

200 μM
Incubation Time:

2, 8, 24 h
Result:

Showed strong colocalization with lysosomes after 8 hours of incubation, with average Pearson’s correlation coefficients of 0.8 in both cell lines.
Maintained high colocalization coefficients across all time points for NLBPD and FLBPD, while CLBPD showed a decrease in colocalization at 24 hours in both cell lines.
Exhibited fluorescence across cellular membranes, indicating non-exclusive lysosomal localization.

Cell Viability Assay^[1]

Cell Line:

MIA PaCa-2, PANC-1 3D microtumor cultures
Concentration:

25, 50, 100, 200, 250 μM (dark toxicity); 100 μM (uptake kinetics)
Incubation Time:

24 h (dark toxicity); 30 minutes, 1, 2, 4, 8, 16, 24 h (uptake kinetics)
Result:

Increased in uptake over time, with maximal uptake observed at 24 hours.
Showed the highest uptake for CLBPD in PANC-1 microtumors.
Demonstrated non-toxicity at 100 μM to microtumors.

Cell Viability Assay^[1]

Cell Line:

MIA PaCa-2, PANC-1 3D microtumor cultures
Concentration:

100 μM
Incubation Time:

8 h
Result:

Reduced MIA PaCa-2 microtumor viability to 55%, 59%, and 50% respectively for NLBPD, FLBPD, or CLBPD monotherapy.
Reduced MIA PaCa-2 microtumor viability to 20% when combining FLBPD PDT with oxaliplatin, a significant decrease compared to monotherapies.
Achieved a global synergy score of 29.41 for MIA PaCa-2, with radiant exposures ≥2.5 J/cm² synergistic with all oxaliplatin doses.
Maintained PANC-1 microtumor viability at 71%, 68%, and 74% respectively for NLBPD, FLBPD, or CLBPD monotherapy.
Reduced PANC-1 microtumor viability to 45%, 56%, and 56% respectively when combining NLBPD, FLBPD, or CLBPD PDT with oxaliplatin.
Achieved a global synergy score of 8.75 for PANC-1, with synergy observed at select dose combinations.
Diminished combination treatment efficacy in both cell lines when dynasore was added.

In Vivo

Verteporfin liposome (0.5 mg/kg; i.p.) in low-dose photodynamic therapy (PDT), in combination with Oxaliplatin (HY-17371), inhibits the growth of orthotopic pancreatic tumors in nude mice, showing superior efficacy compared to Oxaliplatin monotherapy^[1].
Verteporfin liposome (intravenous injection; single dose) achieves higher tumor tissue concentrations in tumor-bearing mice with abundant LDL receptors than water-soluble Verteporfin (HY-B0146)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Rj: NMRI-Foxn1nu/nu nude mice (female, 6 weeks old, orthotopic implantation of luciferase-expressing PANC-1 cells)^[1]
Dosage:

0.5 mg/kg (liposomal verteporfin); 5 mg/kg (oxaliplatin)
Administration:

i.p. (liposomal verteporfin, followed by 690 nm light irradiation at 150 mW/cm² for 50 J/cm²); i.p. (oxaliplatin, immediate post-irradiation)
Result:

Achieved the lowest tumor volumes and heterogeneity compared to monotherapies or sham treatment.
Showed 58% of mice had tumor response, with mean bioluminescence signal reduction significantly greater than oxaliplatin monotherapy and near-significantly greater than PDT monotherapy.
Maintained stable body weight profiles confirming tolerability.

Chemical Information

SMILES

[Verteporfin liposome]
Synonyms

Liposomal verteporfin
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Carigga Gutierrez NM, et al. Photochemical internalization with verteporfin-liposomes enhances oxaliplatin retention and efficacy in models of pancreatic cancer. Journal of controlled release : official journal of the Controlled Release Society. 2025 Nov 10;387:114201.

[2]. Ansar SM, et al. Analysis of verteporfin liposomal formulations for phospholipids and phospholipid degradation products by liquid chromatography-mass spectrometry (LC-MS). Journal of pharmaceutical and biomedical analysis. 2022 Jan 20;208:114473. [Content Brief]

[3]. Keam SJ, et al. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation. Drugs. 2003;63(22):2521-54.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Verteporfin liposome

Alle YAP Isoform-spezifische Produkte anzeigen